Jasper Therapeutics, Inc.

JSPR

US4718712023

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
25.96 ^USD	+7.72%		+8.53%	+229.02%

05-20	Transcript : Jasper Therapeutics, Inc. - Special Call
05-13	Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	MT

Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 08, 2023 at 09:11 pm

Jasper Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 37.69 million compared to USD 30.64 million a year ago. Basic loss per share from continuing operations was USD 10.3 compared to USD 26.9 a year ago.

Latest news about Jasper Therapeutics, Inc.

Transcript : Jasper Therapeutics, Inc. - Special Call	05-20
Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	05-13	MT
Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients	05-13	CI
Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	05-06	CI
Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	05-06	CI
Certain Common Stock of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	05-06	CI
HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target	05-06	MT
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	04-03	MT
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	03-28	MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	03-19	CI
TD Cowen Initiates Jasper Therapeutics With Outperform Rating	03-18	MT
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia	03-15	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-04	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-04	CI
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise	02-06	MT
Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023	12-10	CI
Jasper Therapeutics Says First Patient Dosed in Phase 1b/2a Trial of Briquilimab for CSU Treatment	11-30	MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria	11-30	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023	11-02	CI
Jasper Therapeutics, Inc. Announces Board Changes	11-01	CI
Transcript : Jasper Therapeutics, Inc. - Special Call	11/10/23
Jasper Therapeutics Appoints Herb Cross as CFO	25/09/23	MT
Jasper Therapeutics, Inc. Appointed Herb Cross, as Corporate Secretary	25/09/23	CI
Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes	25/09/23	CI

Chart Jasper Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Sector

Pharmaceuticals

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.96 USD

Average target price

62.83 USD

Spread / Average Target

+142.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JASPER THERAPEUTICS, INC.	+229.02%	364M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals